Levasseur L M, Slocum H K, Rustum Y M, Greco W R
Department of Biomathematics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
Cancer Res. 1998 Dec 15;58(24):5749-61.
For potential clinical extrapolation of in vitro findings, it is of interest to relate the measured effect of an anticancer agent to concentration and exposure time. The Hill model (A. V. Hill, J. Physiol., 40: iv-vii, 1910) is commonly used to describe pharmacodynamic (PD) effects, including drug-induced growth inhibition of cancer cells in vitro. The IC(X)n x T = k relationship, in which IC(X) is the concentration of agent required to reduce cell growth by X%, T is the exposure time, and n and k are estimable parameters, was first applied to bacterial disinfectant action and then was successfully used to model anticancer drug potency as a function of exposure time (D. J. Adams, Cancer Res., 49: 6615-6620, 1989). Our goal was to create a new global PD modeling paradigm to facilitate the quantitative assessment of the growth-inhibitory effect of anticancer agents as a function of concentration and exposure time. Wild-type human ovarian A2780 and ileocecal HCT-8 carcinoma cells and sublines that were resistant to cisplatin (A2780/CP3), doxorubicin (A2780/DX5B), and raltitrexed (RTX) (HCT-8/DW2) were exposed to various anticancer agents, cisplatin, doxorubicin, paclitaxel, trimetrexate, RTX, methotrexate, and AG2034, for periods ranging from 1 to 96 h. Cell growth inhibition was measured with the sulforhodamine B protein dye assay. Patterns of time-dependency of drug potency, slope of the concentration-effect curves, and relative degree of resistance were characterized. Empirical mathematical expressions were built into a global concentration-time-effect model. The global PD model was then fit to the concentration-time-effect data with iteratively reweighted nonlinear regression. Under specific treatment conditions, the examination of the slope and the shape of the concentration-effect curves revealed a large heterogeneity in drug response, e.g., shallow concentration-effect curve or double or triple Hill "roller coaster" concentration-effect curve. These patterns, which were observed at intermediate exposure times in parental and resistant cells for paclitaxel and trimetrexate or only in resistant HCT-8/DW2 cells for RTX, methotrexate, and AG2034, revealed mechanistic insights for the former cases but possible methodological artifacts for the latter cases. The comprehensive PD modeling of the cytotoxic effect of anticancer agents showed that it was possible to modulate drug effect, response heterogeneity, and drug resistance by altering the time of exposure to the agents. This approach will be useful for: (a) describing complex concentration-time-effect surfaces; (b) refining biological interpretations of data; (c) providing insights on mechanisms of drug action and resistance; and (d) generating leads for clinical use of anticancer drugs.
为了将体外研究结果进行潜在的临床外推,将抗癌药物的测量效应与浓度和暴露时间联系起来很有意义。希尔模型(A.V.希尔,《生理学杂志》,40: iv - vii,1910)通常用于描述药效学(PD)效应,包括体外药物诱导的癌细胞生长抑制。IC(X)n x T = k关系,其中IC(X)是使细胞生长降低X%所需的药物浓度,T是暴露时间,n和k是可估计参数,最初应用于细菌消毒作用,随后成功用于将抗癌药物效力建模为暴露时间的函数(D.J.亚当斯,《癌症研究》,49: 6615 - 6620,1989)。我们的目标是创建一种新的全局PD建模范式,以促进对抗癌药物生长抑制效应作为浓度和暴露时间函数的定量评估。将野生型人卵巢A2780和回盲部HCT - 8癌细胞以及对顺铂(A2780/CP3)、阿霉素(A2780/DX5B)和雷替曲塞(RTX)(HCT - 8/DW2)耐药的亚系暴露于各种抗癌药物,顺铂、阿霉素、紫杉醇、三甲曲沙、RTX、甲氨蝶呤和AG2034,暴露时间为1至96小时。用磺酰罗丹明B蛋白质染料测定法测量细胞生长抑制。表征了药物效力的时间依赖性模式、浓度 - 效应曲线的斜率和相对耐药程度。将经验数学表达式纳入全局浓度 - 时间 - 效应模型。然后用迭代加权非线性回归将全局PD模型拟合到浓度 - 时间 - 效应数据。在特定治疗条件下,对浓度 - 效应曲线的斜率和形状进行检查发现药物反应存在很大异质性,例如浅浓度 - 效应曲线或双或三希尔“过山车”浓度 - 效应曲线。这些模式,在亲本细胞和耐药细胞中紫杉醇和三甲曲沙的中间暴露时间观察到,或仅在耐药的HCT - 8/DW2细胞中RTX、甲氨蝶呤和AG2034观察到,对于前一种情况揭示了机制见解,对于后一种情况则可能是方法学假象。对抗癌药物细胞毒性效应的综合PD建模表明,通过改变药物暴露时间可以调节药物效应、反应异质性和耐药性。这种方法将有助于:(a)描述复杂的浓度 - 时间 - 效应表面;(b)完善数据的生物学解释;(c)提供关于药物作用和耐药机制的见解;(d)为抗癌药物的临床应用产生线索。